Brief: Herantis Pharma Reports Delay Of Lymfactin Phase 1 Study

Herantis Pharma Oyj

27/12/2017 07:00

Dec 27 (Reuters) - Herantis Pharma Oyj  HRTIS.HE : 
    * REG-HERANTIS PHARMA EXPANDS ON TIMELINE FOR LYMFACTIN 
STUDIES 
    * ANNOUNCES A SLIGHT DELAY IN COMPLETING PATIENT RECRUITMENT 
IN 
CLINICAL PHASE 1 STUDY WITH LYMFACTIN 
    * PATIENT RECRUITMENT IS EXPECTED TO BE COMPLETED IN Q1 OF 
2018 
INSTEAD OF BY END OF 2017 
 
Source text for Eikon:  ID:nGNE14k5ZX  
Further company coverage:  HRTIS.HE  
 
 (Gdynia Newsroom) 
 ((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))